Researchers found an association between methyltransferases like 3 (METTL3) expression and poor prognosis in patients with intrahepatic cholangiocarcinoma (iCCA), as published in Oncogene. METTL3 promoted iCCA progression, suggesting that it might be a potential therapeutic target for the disease.

“Mechanistically, we found that [tri-methylation of lysine 4 on histone 3] activation-driven transcription is the reason for the dysregulation of METTL3 in [iCCA],” the authors wrote.

MTTL3 was found to be upregulated in 3 different iCCA datasets. Immunohistochemistry analysis of paraffin-embedded specimens of 96 patients with iCCA revealed that MTTL3 expression was positively correlated with tumor size and tumor, node, metastasis stage.

Continue Reading

Moreover, patients with high METTL3 expression had poorer disease-free survival and overall survival (OS). These results were further supported by multivariate regression analysis, which highlighted METTL3 expression as an independent predictor of OS in patients with iCCA.

Learn about cholangiocarcinoma prognosis

Knockdown of MTTL3 inhibited the proliferation of iCCA cells, while its overexpression led to opposite effects and drove iCCA progression. Accordingly, treating cells with STM2457, a selective METTL3 inhibitor, also inhibited proliferation, invasion, and migration in a dose-dependent manner, while promoting apoptosis and cell cycle arrest at S-phase.

At the molecular level, METTL3 downregulated the expression of the interferon-induced protein with tetratricopeptide repeats 2 (IFIT2). IFIT2 is involved in the innate immune response, being a direct response target of type-I interferons. It has been proposed as a tumor suppressor in several cancers.

MTTL3-mediated downregulation of IFIT2 was shown to be dependent on YTH domain-containing family protein 2 (YTHDF2), which is known to induce the degradation of mRNAs by reading N6-methyadenosine modification sites.


Xu Q-C, Tien Y-C, Shi Y-H, et al. METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Oncogene. Published online January 29, 2022. doi:10.1038/s41388-022-02185-1